



## Supplementary Information

**Supplementary Table S1.** Coordinates of protein kinases in the phospho-kinase dot blot array.

Membrane/Coordinate	Target/Control		
A-A1, A2	Reference spot	A-D5, D6	Lck
A-A3, A4	p38alpha	A-D7, D8	STAT2
A-A5, A6	ERK1/2	A-D9, D10	STAT5a
A-A7, A8	JNK1/2/3	B-D11, D-12	p70 S6 Kinase
A-A9, A10	GSK-3alpha/beta	B-D13, D14	RSK1/2/3
B-A13, A14	p53	B-D15, D16	Enos
B-A17, A18	Reference spot	A-E1, E2	Fyn
A-B3, B4	EGFR	A-E3, E4	Yes
A-B5, B6	MSK1/2	A-E5, E6	Fgr
A-B7, B8	AMPK alpha1	A-E7, E8	STAT6
A-B9, B10	Akt1/2/3	A-E9, E-10	STAT5b
B-B11, B12	Akt1/2/3	B-E11, E12	STAT3
B-B13, B14	p53	B-E13, E14	p27
A-C1, C2	TOR	B-E15, E16	PLC- $\gamma$ 1
A-C3, C4	CREB	A-F1, F2	Hck
A-C5, C6	HSP27	A-F3, F4	Chk-2
A-C7, C8	AMPK alpha2	A-F5, F6	FAK
A-C9, C10	beta-catenin	A-F7, F8	PDGFR $\beta$
B-C11, C12	p70 S6 Kinase	A-F9, F10	STAT5a/b
B-C13, C14	p53	B-F11, F12	STAT3
B-C15, C16	c-Jun	B-F13, F14	WNK1
A-D1, D2	Src	B-F15, F16	PYK2
A-D3, D4	Lyn	B-G1, G2	Reference spot
		B-G3, G4	PRAS40
		A-G9, G10	PBS(Negative Control)
		B-G11, G12	HSP60
		B-G17, G18	PBS(Negative Control)






(b)

TNBC subtype	Cell line	Mutations	Ethnicity
<b>Basal Like</b>			
BL1	HCC1937	BRCA1; TP53; MAPK13; MDC1	Caucasian
BL1	MDA-MB-468	PTEN; RB1; SMAD4; TP53	African-American
BL2	HCC70	PTEN; TP53	African-American
BL2	HCC1806	CDKN2A; TP53; UTX	African-American
<b>Mesenchymal like</b>			
M	BT-549	PTEN; RB1; TP53	Caucasian
MSL	H5578T	CDKN2A; HRAS; TP53	Caucasian
MSL	MDA-MB-157	NF1; TP53	African-American
MSL	MDA-MB-231	BRAF; CDKN2A; KRAS; NF2; TP53; PDGFRA	Caucasian
<b>Unclassified</b>			
-	BT20	CDKN2A; PIK3CA; TP53	Caucasian


Source: J. Kao et al., PLoS One 4 (2009) e6146

**Supplementary Figure S1.** (a) Migration of TNBC cells into the cell-excluded gap after 48 hrs without any treatment. (b) Subtypes of TNBC cell lines and their major mutations.





**Supplementary Figure S2.** Basal-like HCC1937 cells migrated into and occupied the gap almost within 24 hrs. Scale bar is 1 mm.


(a) Fisetin treatments




(b) Quercetin treatments




**Supplementary Figure S3.** Cytotoxicity analysis TNBC cells treated with (a) fisetin and (b) quercetin. Each data point represents the mean of 8 samples and error bars represent standard error from the mean. (c-e) Representative images of Hs578T show that the spindle-like mesenchymal morphology of cells changes to epithelial cell morphology with fisetin and quercetin treatments. Note that with fisetin treatment of HCC1806 cells and quercetin treatment of HCC1937 cells, a sigmoidal curve could not be fitted to the dose response data.




**Supplementary Figure S4.** Baseline relative phosphorylation of 43 protein kinases and 2 related signaling proteins in nine TNBC cell lines without any treatments. The hierarchical clustering identified 4 major clusters: Cluster 1 is highlighted with a red box (high baseline activity), Cluster 2 is highlighted with an orange box (high to moderate baseline activity), Cluster 3 is highlighted with a green box (moderate baseline activity), and Cluster 4 is highlighted with blue box (low baseline activity).




**Supplementary Figure S5.** Fisetin and quercetin treatments are non-cytotoxic to TNBC cells. Viability of nine TNBC cell lines after treatments with (a) 200  $\mu$ M fisetin and (b) 200  $\mu$ M quercetin for 6 hours.



**Supplementary Figure S6.** GSK1059615 treatment dose-dependently downregulated p-WNK1. (a-d) Western blots of p-WNK1 and t-WNK in TNBC cells treated with GSK1059615 for 6 hrs.



**Supplementary Figure S7.** Combination treatment of TNBC cells with GSK1059615 and WNK463 inhibitors produced an additive effect, suggesting that p-WNK1 is a p-AKT effector. (a) Western blot for single agent and combination treatments for 6 hrs. (b-c) Levels of p-AKT/t-AKT and p-WNK1/t-WNK1 in HCC1806 cells, respectively. ns represents lack of statistically significant difference.



**Supplementary Figure S8.** CHK2 inhibition promoted migration of different TNBC cells. Images of cell migration (a-c) without any treatment and (d-f) treatments with BML-277. Scale bar is 1 mm. (g) Quantified increased migration of TNBC cells by CHK2 inhibition. Each bar represents a mean of 8 samples, and error bars represent standard error from mean.